Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform

Core Insights - Rapid Micro Biosystems has received a new multi-system order from Samsung Biologics to expand the Growth Direct platform for automated microbial quality control [1][2][3] Company Overview - Rapid Micro Biosystems is a life sciences technology company that provides automation solutions for the efficient manufacturing and safe release of healthcare products, including biologics, vaccines, and sterile injectables [4] - The flagship Growth Direct system modernizes manual microbial quality control testing workflows, enhancing operational efficiency, accuracy, and compliance with data integrity regulations [4] Partnership Details - The follow-on order from Samsung Biologics strengthens the existing partnership and supports the automation of microbial quality control across Samsung's manufacturing network [2][3] - The Growth Direct platform is designed to deliver faster results, greater accuracy, and improved data integrity, which are critical for maintaining high productivity and quality in manufacturing operations [3]